Soligenix (NASDAQ: SNGX) announced the publication of positive results from its comparability study evaluating HyBryte (TM) versus Valchlor (R) for the treatment of cutaneous T-cell lymphoma in ...
Soligenix (NASDAQ: SNGX) announced the publication of positive results from its comparability study evaluating HyBryte(TM) versus Valchlor(R) for the treatment of cutaneous T-cell lymphoma in Oncology ...
Treatment with the investigational base-editing gene therapy ristoglogene autogetemcel (risto-cel) showed promise in patients with sickle cell disease, according to an interim ana ...
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
Soligenix (NASDAQ: SNGX) announced the European Commission has granted orphan drug designation to dusquetide (SGX945) for the ...
Soligenix (NASDAQ: SNGX) announced the European Commission has granted orphan drug designation to dusquetide (SGX945) ...
People are buying helmets, face masks, vests and beds that emit long-wavelength light. Beneath the hype, there is some ...
Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell ...
Highlighting Positive Results in Comparison to Valchlor® and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: ...
Purpose: To conduct a systematic review of the mechanisms of photobiomodulation therapy (PBMT) for treating or preventing oral mucositis (OM) caused by antineoplastic therapy. Methods: Following ...
DelveInsight's, “Oral Mucositis Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Oral Mucositis pipeline landscape. It covers the Oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results